Course Videos
What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? And how does this test compare to tissue-based NGS? Which patients will benefit most?
Since assessing tumor mutational burden requires whole exome NGS profiling, and given the emerging pervasiveness of immunotherapy for many tumor types, how do you decide which tumor subtypes and patients, especially those with advanced ...
What are the current actionable interfaces between NGS-based whole exome profiling and immunotherapy, focusing on new data related to tumor mutational burden, microsatellite instability (MSI), and related signatures?
What have we learned from the recent trials looking at the ability of NGS to drive precision-based treatments across a broad spectrum of tumor subtypes?
What specific information, variances, actionable guidance, and clinical/biological interpretations are provided on a NGS pathology report? How do you apply an NGS report clinically?
What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers identified by NGS will produce treatments that are better aligned with actionable targets and will improve patient outcomes?
How do you prioritize the genomic information provided by NGS and how do you curate the importance of alterations, rearrangements, and fusion events reported by NGS?
In South Korea, how is NGS playing an increasingly important role in the Yonsei Cancer Center in the genomic profiling of cancer and to guide selection of oncology treatment?
What specific information, variances, actionable guidance, and clinical/biological interpretations are provided on a NGS pathology report? How do you deal with uncertainties and variations of unknown significance? And with frame shifts?
What kind of tissue samples and cellularity are required for accurate and actionable NGS?
What kind of tissue samples and cellularity are required for accurate and actionable NGS?
What is the rationale for using genome-wide NGS in the setting of precision cancer medicine?
What is the rationale for using genome-wide NGS in the setting of precision cancer medicine?
What is the range of mutational rearrangements and alterations that can be identified by hybrid capture-based NGS and that have clinical applications?